Guardant Health agreed to acquire MetaSight Diagnostics for $59 million plus up to $90 million in milestones, adding mass‑spectrometry–based metabolomics and lipidomics to Guardant’s portfolio. The acquisition aims to enhance the Shield blood test for colorectal cancer screening—an assay that received FDA breakthrough device designation in 2025—and to accelerate multi‑omics biomarker development for early detection. Guardant cited commercial growth projections and a recent collaboration with Merck as context for the transaction, which executives say will strengthen clinical utility and competitive positioning in the liquid‑biopsy diagnostics market.